Matching articles for "Kisunla"
Issue 1751 · March 30, 2026
Drugs for Dementia

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and…

Med Lett Drugs Ther. 2026 Mar 30; 68(1751):49-56 doi:10.58347/tml.2026.1751a
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia.
Issue 1751 · March 30, 2026
Comparison Table: Drugs for Alzheimer's Disease Dementia (online only)

View the Comparison Table: Drugs for Alzheimer's Disease Dementia

Med Lett Drugs Ther. 2026 Mar 30; 68(1751):e57-8 doi:10.58347/tml.2026.1751c
View the Comparison Table: Drugs for Alzheimer's Disease Dementia
Issue 1751 · March 30, 2026
Comparison Table: Amyloid Beta-Directed Antibodies for Alzheimer's Disease (online only)

View the Comparison Table: Amyloid Beta-Directed Antibodies for Alzheimer's Disease

Med Lett Drugs Ther. 2026 Mar 30; 68(1751):e59-60 doi:10.58347/tml.2026.1751d
View the Comparison Table: Amyloid Beta-Directed Antibodies for Alzheimer's Disease
Issue 1747 · February 2, 2026
Elecsys — A Second Blood Test for Alzheimer's Disease

Elecsys Phospho-Tau (181P) Plasma (Roche), a blood-based diagnostic test, has been cleared by the FDA to aid in the initial assessment of amyloid plaque pathology associated with Alzheimer's disease (AD) in…

Med Lett Drugs Ther. 2026 Feb 2; 68(1747):18-20 doi:10.58347/tml.2026.1747b
Elecsys Phospho-Tau (181P) Plasma (Roche), a blood-based diagnostic test, has been cleared by the FDA to aid in the initial assessment of amyloid plaque pathology associated with Alzheimer's disease (AD) in patients ≥55 years old with signs of cognitive decline. It is the second blood test for AD biomarkers to be cleared by the FDA; the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test was cleared in 2025 (see Table 1).
Issue 1741 · November 10, 2025 Free
In Brief: Updates for Lecanemab (Leqembi) for Alzheimer's Disease

The FDA has recommended additional MRI monitoring during initiation of treatment with the amyloid beta-directed monoclonal antibody lecanemab-irmb (Leqembi) and has approved a new subcutaneously injected…

Med Lett Drugs Ther. 2025 Nov 10; 67(1741):182-3 doi:10.58347/tml.2025.1741d
The FDA has recommended additional MRI monitoring during initiation of treatment with the amyloid beta-directed monoclonal antibody lecanemab-irmb (Leqembi) and has approved a new subcutaneously injected formulation of the drug (Leqembi Iqlik) for maintenance treatment of Alzheimer's disease.
Issue 1735 · August 18, 2025 Free
In Brief: A New Donanemab (Kisunla) Dosing Regimen for Alzheimer's Disease

The FDA has approved a new titration regimen for donanemab ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody indicated for treatment of Alzheimer's disease. The new regimen is intended to…

Med Lett Drugs Ther. 2025 Aug 18; 67(1735):134-5 doi:10.58347/tml.2025.1735d
The FDA has approved a new titration regimen for donanemab ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody indicated for treatment of Alzheimer's disease. The new regimen is intended to reduce the risk of serious amyloid-related imaging abnormalities (ARIA) associated with use of the drug.
Issue 1732 · July 7, 2025
A Blood Test for Alzheimer's Disease

The FDA has cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Fujirebio), a bloodbased diagnostic test, for early detection of amyloid plaque pathology associated with Alzheimer's disease (AD) in…

Med Lett Drugs Ther. 2025 Jul 7; 67(1732):109 doi:10.58347/tml.2025.1732b
The FDA has cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Fujirebio), a bloodbased diagnostic test, for early detection of amyloid plaque pathology associated with Alzheimer's disease (AD) in adults ≥50 years old who are showing signs and symptoms of the disease. The new assay is the first blood test for amyloid biomarkers to become commercially available in the US. The Lumipulse G β-Amyloid Ratio (1-42/1-40), which measures amyloid biomarkers in cerebrospinal fluid (CSF), was cleared by the FDA in 2022.
Issue 1709 · August 19, 2024
Donanemab (Kisunla) for Alzheimer's Disease

Donanemab-azbt ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):129-31 doi:10.58347/tml.2024.1709a
Donanemab-azbt ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be started in patients with mild cognitive impairment (MCI) or mild dementia. Donanemab is the third IV amyloid beta-directed monoclonal antibody to be marketed in the US. Lecanemab ( Leqembi – Biogen/Eisai) was approved by the FDA in 2023 for the same indication as donanemab. Aducanumab ( Aduhelm – Lilly) was granted accelerated approval in 2021, but it was withdrawn from the market earlier this year for commercial reasons.
Issue 1708 · August 5, 2024 Free
Table: Amyloid-Directed Antibodies for Alzheimer's Disease (online only)

View the Table: Amyloid-Directed Antibodies for Alzheimer's Disease

Med Lett Drugs Ther. 2024 Aug 5; 66(1708):e1-2 doi:10.58347/tml.2024.1708e
View the Table: Amyloid-Directed Antibodies for Alzheimer's Disease
Issue 1657 · August 22, 2022
Comparison Table: Drugs for Alzheimer's Disease (online only)

View the Comparison Table: Drugs for Alzheimer's Disease

Med Lett Drugs Ther. 2022 Aug 22; 64(1657):e136-7
View the Comparison Table: Drugs for Alzheimer's Disease